title: [What is needed to prevent defaulting from tuberculosis treatment?].
abstract: OBJECTIVE
  To investigate the factors relating to defaulting from tuberculosis treatment in Japan, and clarify what is needed to prevent defaulting.
  
  
  OBJECTIVE
  Tuberculosis patients who were registered at public health centers (PHCs), and interrupted treatment for more than 2 months without the doctors' direction at the end of December 2005.
  
  
  METHODS
  Investigation by questionaire sent by post-mail to all public health centers (608 PHCs) in Japan.
  
  
  RESULTS
  The valid answers was obtained from 89.0% (541/ 608) of PHCs. Tuberculosis patients who had interrupted treatment, but could be contacted by PHCs' staff were 137, and for those patients the factors relating to defaulting from treatment were analyzed. The factors were classified into 7 categories (there may be more than one factors in one patients); factors related to disbelief and/or prejudice for diagnosis and/or treatment (except factors related to drug adverse effects) were observed in 51.8%, factors related to economical problem in 24.1%, factors related to job or studies in 23.4%, factors related to drug adverse effects in 22.6%, factors related to visiting out-patients departments in 6.6%, psychiatric disease and/or drug abuse in 4.4%, others in 9.5%.
  
  
  CONCLUSIONS
  It is needed to prevent defaulting, first, to improve the quality of tuberculosis medical care and services including good and sufficient explanations on TB and how to cure it to patients, and proper managements for drug adverse effects, and then to expand public economical support for the costs of medicine and travel expenses to medical facilities and to make accessible time and place of the tuberculosis outpatient clinic more convenient and flexible for patients.
authors.affiliation: Research Institute of Tuberculosis, JATA, 3-1-24, Matsuyama, Kiyose-shi, Tokyo 204-8533 Japan. ito@jata.or.jp
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Ito
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshiyama
authors.forename: Yohko
authors.initials: Y
authors.lastname: Nagata
authors.forename: Noriko
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Seiya
authors.initials: S
authors.lastname: Kato
authors.forename: Nobukatsu
authors.initials: N
authors.lastname: Ishikawa
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use; D005378:Financial Support; D006297:Health Services Accessibility; D007564:Japan / Q000453:epidemiology; D001523:Mental Disorders; D010352:Patient Dropouts / Q000706:statistics & numerical data; D011787:Quality of Health Care; D012944:Social Support; D019966:Substance-Related Disorders; D011795:Surveys and Questionnaires; D014376:Tuberculosis / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control* / Q000523:psychology
chemical_list: D000995:Antitubercular Agents